Stock Detail
DENDREON CORPORATION
Biotechnology
DNDN @ Yahoo Finance | DNDN Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $7.51 | $8.09 | $0.30 | 4.16% | 0.00 | $7.21 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $7.19 | $7.07 | 12.73M | 1.12B | 6.43M | 0.00 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 8.58 | 8.05 | 7.56 | 7.03 | 6.54 |
Stock Profile
Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of targeted therapies for cancer. Its portfolio of product candidates includes therapeutic vaccines, monoclonal antibodies, and small molecules to treat a range of cancers. The company's lead product candidate, Provenge (sipuleucel-T), is an investigational active cellular immunotherapy in Phase III clinical trials for the treatment of metastatic, androgen independent prostate cancer. In addition, Dendreon completed Phase I clinical trials for Neuvenge (lapuleucel-T), an investigational active cellular immunotherapy for the treatment of breast, ovarian, and other solid tumors. Its preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease product candidates for the treatment of cancer. The company has research and development alliances with Genentech, Inc.; Abgenix, Inc.; and Dyax Corp. Dendreon was formed in 1992 and is headquartered in Seattle, Washington.